MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
6.99
-0.40
-5.41%
After Hours: 7.90 +0.91 +13.02% 16:27 11/20 EST
OPEN
7.35
PREV CLOSE
7.39
HIGH
7.56
LOW
6.97
VOLUME
295.67K
TURNOVER
--
52 WEEK HIGH
17.43
52 WEEK LOW
5.06
MARKET CAP
111.01M
P/E (TTM)
-1.8084
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Immunic (IMUX)
TipRanks · 2d ago
Immunic: Buy Rating and $22 Price Target Maintained Ahead of ENSURE Phase 3 MS Results
TipRanks · 4d ago
Weekly Report: what happened at IMUX last week (1109-1113)?
Weekly Report · 4d ago
Morning Movers: Microsoft lower amid continued outage of 365 services
TipRanks · 11/13 13:55
Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026
NASDAQ · 11/13 11:59
Immunic reports Q3 EPS (99c), consensus (95c)
TipRanks · 11/13 11:35
Immunic Q3 EPS $(0.99) Misses $(0.96) Estimate
Benzinga · 11/13 11:34
Immunic GAAP EPS of -$0.99 misses by $0.04
Seeking Alpha · 11/13 11:32
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.